• Immune Biosolutions will continue its growth at EspaceLabz

    Immune Biosolutions, a JLABS @ Toronto resident, is pleased to announce the relocation of its Sherbrooke headquarters and laboratories in the new EspaceLabz center, located in the Sherbrooke’s Scientific Park. In addition to providing additional space, the new facility will grant access to state-of-the-art equipment to follow the increasing demand for Immune Biosolutions' Nebula Antibody Platform, and will allow additional R&D initiatives in the development of new life- saving technologies. This marks an important milestone for Immune Biosolutions. With recent...
  • Towards global commercialization

    100 000 $ for development and commercialization Today, Canada Economic Development (CED) in collaboration with Accélérateur de création d’entreprises technologiques (ACET) announced funding for 5 innovative businesses to accelerate their development by intensifying their commercialization activities. "The Government of Canada is committed to supporting Canadian businesses that are focused on innovation." -The Honourable Navdeep Bains, Minister responsible for CED The 100 000$ contribution will be used by Immune Biosolutions to implement its plan to tackle the pharmaceutical and biotechnology markets...
  • G Protein-Coupled Receptors targeted by antibodies raised against three dimensional epitopes

    Why target GPCRs with antibodies?

    The G Protein-coupled receptor (GPCR) superfamily represents the largest and single most important family of human drug targets. GPCRs play a central role in a plethora of biological processes and are linked to a wide range of therapeutic areas including cancer, diabetes, inflammation, cardiovascular diseases, and chronic pain. Expressed in every type of cell in the body, GPCRs relay signals from outside the cell, across the membrane, to intracellular signaling pathways.

    Continue reading

Items 11 to 13 of 13 total

  1. 1
  2. 2